Valiant Laboratories Q1FY27 Consolidated Profit Surges to ₹2,110 Lakhs
Valiant Laboratories reported its Q1 FY27 results. Consolidated net profit surged to ₹2,110.30 lakhs from ₹182.09 lakhs year-on-year. Standalone net profit was ₹947.88 lakhs, up from ₹181.56 lakhs. Revenue from operations also saw significant growth on both consolidated and standalone bases.
The substantial increase in profits and revenue for the quarter is a material positive development for the company's financial performance and is likely to impact investor sentiment positively.
The company reported a significant increase in net profit on both consolidated and standalone bases, along with substantial revenue growth, indicating strong financial performance.
Valiant Laboratories Limited announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, following a Board of Directors meeting held on August 10, 2026. The meeting, which commenced at 4:30 PM and concluded at 6:00 PM, also saw the Audit Committee review the financial statements.
For the quarter ended June 30, 2026, the company reported a consolidated net profit of ₹2,110.30 lakhs. This represents a significant increase compared to the ₹182.09 lakhs reported in the corresponding quarter of the previous year. Consolidated revenue from operations stood at ₹11,528.51 lakhs, a substantial rise from ₹4,682.27 lakhs in the same period last year.
On a standalone basis, the net profit for the quarter ended June 30, 2026, was ₹947.88 lakhs, an improvement from ₹181.56 lakhs in the prior year's quarter. Standalone revenue from operations reached ₹7,342.11 lakhs, up from ₹5,100.73 lakhs in the same quarter of the previous year.
The company's financial results were audited by Raman S. Shah & Co., Chartered Accountants, who issued an unqualified audit report for both standalone and consolidated statements. The results have been uploaded on the company's website and will be available on the BSE and NSE websites.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.